Understanding rare lipid disorders and their effects over time

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the natural history of uncommon dyslipidemias and rare lipid disorders, focusing on how these conditions evolve and respond to therapies over time. Participants aged 10 years and older, both in the U.S. and internationally, will be enrolled to provide data on lipid levels and cardiovascular risk markers. The study will utilize both conventional and virtual methods to collect patient data and specimens, with the goal of developing new diagnostic tools and improving patient health outcomes.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA:

Affected Participants

* Male and female participants age \>= 10 years.
* Subjects with confirmed or suspected rare disorder that causes lipid/lipoprotein abnormalities (dyslipidemia) or abnormal documented or referred atherosclerosis patterns.
* Only affected individuals (not healthy volunteers and for self-referred subjects independent of lipid and lipoprotein marker values.); subjects with laboratory or clinical presentation that in the opinion of the Principal Investigator, would alter the determination of normal

parameters for assays and screening tools development.

-Ability of the subject or Legally Authorized Representative (LAR) to understand and willingness to sign a written informed consent document.

Healthy Volunteers

* Participants must be healthy, with no known history of lipid disorders or related medical conditions.
* Participants must not be pregnant.

EXCLUSION CRITERIA:

* Patients with disorders that cause common secondary/lipoprotein alterations.
* Patients with any other findings that, in the opinion of the Principal Investigator, would preclude them from participating in the study.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Marcelo J Amar, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Joy Lynne V Freeman
• Email: joylynne.freeman@nih.gov
• Phone: (301) 480-7632

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Moderate-Intensity Statin + Ezetimibe vs High-Intensity Statin in CKD with ASCVD

  In adults with chronic kidney disease and established cardiovascular disease, this study tests whether a moderate-intensity statin plus ezetimibe can match the benefits of a high-intensity statin alone over three years.

  Recruiting Yonsei University · Seoul · NCT07524101

• Investigating body fat distribution and its impact on metabolic diseases in Japanese adults

  This study looks at how the way body fat is distributed affects the risk of metabolic and heart diseases in Japanese adults.

  Recruiting Osaka Metropolitan University · Sakai, Osaka · NCT06694012

• Effect of choline fenofibrate on carotid atherosclerosis in type 2 diabetes patients

  This study is testing if a medication called choline fenofibrate can help slow down the buildup of plaque in the arteries of Korean patients with type 2 diabetes and high cholesterol.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT05365425

• Observational study of achieving LDL targets with Rovazet tablets in dyslipidemia

  This study follows patients with dyslipidemia who are prescribed Rovazet to see how well reaching LDL targets works in routine care over 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07924345

• Pudendal artery plaque and erectile dysfunction in men with heart disease

  A small study tests whether plaque in the internal pudendal arteries is linked to erectile function in men with coronary artery disease who are undergoing coronary angiography.

  Recruiting Hospital Central Militar · Mexico City, Mexico City · NCT07856199

• VERVE-102 for adults with or at high risk for heart disease

  This study tests whether VERVE-102 can lower bad cholesterol (LDL-C) compared with a placebo in adults with plaque buildup or high risk for it.

  Recruiting Phase 2 Verve Therapeutics, Inc. · DeSoto, Texas · NCT07839936

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.